MNG1224
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.551
- PROTEIN_SECRETION+0.510
- UV_RESPONSE_DN+0.408
- MITOTIC_SPINDLE+0.381
- UNFOLDED_PROTEIN_RESPONSE+0.323
- MYC_TARGETS_V1+0.297
- PI3K_AKT_MTOR_SIGNALING+0.283
- ANDROGEN_RESPONSE+0.241
- APOPTOSIS+0.174
- WNT_BETA_CATENIN_SIGNALING+0.164
Top 10 suppressed
- ANGIOGENESIS-0.431
- KRAS_SIGNALING_DN-0.348
- ALLOGRAFT_REJECTION-0.329
- ESTROGEN_RESPONSE_LATE-0.318
- CHOLESTEROL_HOMEOSTASIS-0.288
- APICAL_SURFACE-0.283
- MYOGENESIS-0.257
- COAGULATION-0.253
- SPERMATOGENESIS-0.229
- ESTROGEN_RESPONSE_EARLY-0.222
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3304 | Med | Medulloblastoma | 0.843 |
| 2 | MNG1042 | — | — | 0.813 |
| 3 | MNG1043 | — | — | 0.796 |
| 4 | MNG975 | — | — | 0.787 |
| 5 | 24F914FE-3DF0-4286-9231-9D525A777306 | — | — | 0.754 |
| 6 | 68CE8E02-F24A-4580-9881-DFBB288E2ED7 | — | — | 0.750 |
| 7 | SRR934724 | — | — | 0.750 |
| 8 | MNG328 | — | — | 0.740 |
| 9 | SRR934809 | — | — | 0.732 |
| 10 | MNG573 | — | — | 0.732 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.551 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.408 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.381 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.323 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.297 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.283 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.241 | Inavolisib | — uncovered |
| APOPTOSIS | 0.174 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.164 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.151 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.143 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.136 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.134 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.117 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.107 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.097 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.088 | Idelalisib | — uncovered |
| PEROXISOME | 0.039 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.039 | Idelalisib | — uncovered |